Navigation Links
Halozyme Therapeutics to Present at the Jefferies 2012 Global Healthcare Conference
Date:5/31/2012

SAN DIEGO, May 31, 2012 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) will be presenting at the Jefferies 2012 Global Healthcare Conference in New York on Thursday, June 7, 2012 at 12:30 p.m. ET/9:30 a.m. PT. Kurt Gustafson, Chief Financial Officer, Halozyme Therapeutics, will provide a corporate overview.

(Logo:  http://photos.prnewswire.com/prnh/20100302/LA63139LOGO)

The presentation will be webcast through the "Investors" section of Halozyme's corporate website at www.halozyme.com, and a recording will be made available for 90 days following the event. To access the live webcast, please log on to Halozyme's website approximately fifteen minutes prior to the presentation to register and download any necessary audio software.

About Halozyme

Halozyme Therapeutics is a biopharmaceutical company dedicated to developing and commercializing innovative products that advance patient care. With a diversified portfolio of enzymes that target the extracellular matrix, the Company's research focuses primarily on a family of human enzymes, known as hyaluronidases, that increase the absorption and dispersion of biologics. Halozyme's pipeline addresses therapeutic areas, such as diabetes, oncology and dermatology that have significant unmet medical need. The Company markets Hylenex® recombinant (hyaluronidase human injection) and has partnerships with Roche, Baxter, ViroPharma and Intrexon. Halozyme is headquartered in San Diego, CA. For more information on how we are innovating, please visit our corporate website at www.halozyme.com.

Media/Investor Contact:
Anne Erickson
Executive Director
Halozyme Therapeutics
858-704-8264
aerickson@halozyme.com


'/>"/>
SOURCE Halozyme Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Halozyme Reports First Quarter 2012 Financial Results
2. Halozyme to Host First Quarter 2012 Financial Results Conference Call
3. ViroPharma and Halozyme Announce Positive Data of Subcutaneous Cinryze® (C1 esterase inhibitor [human]) with Recombinant Human Hyaluronidase (rHuPH20)
4. Halozyme Therapeutics to Present at the CITI 2012 Global Healthcare Conference
5. Halozyme Announces Exercise in Full of Over-Allotment Option and Completion of Public Offering of Stock
6. Halozyme Announces Proposed Public Offering of Common Stock
7. ViroPharma and Halozyme Therapeutics Announce Positive Data From Initial Phase 2 Assessment of Subcutaneous Cinryze® (C1 esterase inhibitor [human]) with Hyaluronidase (rHuPH20)
8. Halozyme Therapeutics Announces Positive Results From Enzyme-Augmented Insulin Pump Trial
9. Halozyme Therapeutics to Present Data on PEGPH20 at the Upcoming 2011 EORTC-NCI-ASCO Annual Meeting
10. Halozyme Announces Positive Results from Roches Subcutaneous Herceptin Phase 3 Trial
11. Halozyme Begins Randomized, Controlled Clinical Trial with PEGPH20 in Patients with Advanced Pancreatic Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/15/2017)... Mostyn Law and Gulf Coast Regional Blood Center to host ... Mostyn Law family has had 3 members that needed ... Mostyn Law is partnering with Gulf Coast Regional Blood Center ... Blood supplies are running low. Gulf Coast Regional Blood Center,s ... August. That is why the blood center reached out to ...
(Date:8/15/2017)... Calif. , Aug. 15, 2017  AOTI Inc. announced today ... Oxygen Therapy Inc., has recently opened a New York City Office ... ever-increasing usage of its unique Topical Wound Oxygen (TWO 2 ) ... by the Accreditation Commission for Health Care (ACHC) under the company,s ... ...
(Date:8/8/2017)... Israel, Aug. 8, 2017  BioLineRx Ltd. (NASDAQ/TASE: BLRX), ... today reports its financial results for the second quarter ... during the second quarter 2017 and to date: ... clinical development programs for the Company,s lead project, BL-8040: ... pivotal study with BL-8040 as novel stem cell mobilization ...
Breaking Medicine Technology:
(Date:8/23/2017)... ... August 23, 2017 , ... A new ... Orthopaedic Surgeons , points out that therapeutic modalities (physical therapy) is an important ... to the report, a wider scope of physical therapy options is showing promising ...
(Date:8/22/2017)... ... August 22, 2017 , ... The old adage ... as simple as eating healthy foods. But this well-known piece of nutrition advice ... or breaking apart carbohydrates—depends not only on properties of the food but also ...
(Date:8/22/2017)... ... August 22, 2017 , ... ... solutions, announced recently the availability of a new professional fee E/M leveling calculator ... their service to the healthcare industry. E/M coding is complex which supports the ...
(Date:8/22/2017)... ... August 22, 2017 , ... “Wilderness Voices”: a collection ... travel. “Wilderness Voices” is the creation of published author, Martha McKown, an ordained ... was inspired as a very young child when her older sisters studied High School ...
(Date:8/22/2017)... ... August 22, 2017 , ... ... the Founder and Managing Member for t4 Leadership Development & Consulting. He has ... his definition of “success”: physician leadership development, servant leadership, data driven process improvement, ...
Breaking Medicine News(10 mins):